Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

NCT02278185
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Enzalutamide, leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, degarelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome

NCT01441687
View directory record Official record
Conditions
Conditions Influencing Health Status, Healthy, Prostate Cancer
Interventions
laboratory biomarker analysis, transrectal prostate biopsy
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
5
States / cities
Arcadia, California • Duarte, California • Glendora, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

NCT00477087
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Mitoxantrone, GM-CSF
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 31, 2026, 3:19 PM EDT
Active, not recruiting Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

NCT03999515
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Enzalutamide, Erdafitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 31, 2026, 3:19 PM EDT
Completed No phase listed Observational

To Explore Racial Differences in Potential Risk Factors for Developing Prostate Cancer in the VA Population.

NCT00007579
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years to 74 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

NCT04298983
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Recruiting Phase 2 Interventional

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

NCT06100705
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Cypionate, Sipuleucel-T
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

NCT01696994
View directory record Official record
Conditions
Ovarian Carcinoma, Ovarian Germ Cell Tumor
Interventions
Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years · Female only
Enrollment
78,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

NCT01176513
View directory record Official record
Conditions
Prostate Cancer
Interventions
GE-148 (18F)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Not applicable Interventional Results available

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190
View directory record Official record
Conditions
Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
Interventions
Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

NCT07567846
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions
GDC-1261
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 4 Interventional Results available

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

NCT01995513
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Abiraterone, Placebo for Enzalutamide, Prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
6
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 31, 2026, 3:19 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 31, 2026, 3:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men

NCT01447186
View directory record Official record
Conditions
Prostate Cancer, Cancer
Interventions
Post-Test Questionnaire, Interviews, Focus Groups
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
45 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

NCT03081481
View directory record Official record
Conditions
Prostate Cancer
Interventions
PRX302
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
40 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Ocala, Florida • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Trial of HIFU vs. Cryo for Prostate Cancer

NCT06929065
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Stage I, Prostate Cancer Stage II, High Intensity Focused Ultrasound, HIFU, Cryoablation
Interventions
HIFU vs Cryoablation
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Not listed Not applicable Interventional

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

NCT01972867
View directory record Official record
Conditions
Prostate Cancer
Interventions
NanoKnife Procedure
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 31, 2026, 3:19 PM EDT
Recruiting No phase listed Observational

MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer

NCT05241236
View directory record Official record
Conditions
Neoplasms Prostate, Cancer of the Prostate
Interventions
Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
50 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional Results available

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

NCT00661492
View directory record Official record
Conditions
Androgen-independent Prostate Cancer
Interventions
cetuximab, Mitoxantrone
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
55
States / cities
Phoenix, Arizona • Sedona, Arizona • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

NCT00031187
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
11
States / cities
Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 31, 2026, 3:19 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

NCT03833921
View directory record Official record
Conditions
Prostate Cancer Metastatic, Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Martha Mims
Other
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
Interventions
Sacituzumab Govitecan-hziy (SG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT01848067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Alisertib, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 3:19 PM EDT